Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year

1982

Stage

IPO | IPO

Total Raised

$19M

Date of IPO

11/23/1992

About Cortech

Provider of cardiology medical research and development services. The company has three on-going projects: neutrophil elastase inhibitors (NEI), bradykinin antagonists, and antigen-specific immunomodulation. NEIs have considerable potential in treating inflammatory conditions, e.g. adult respiratory distress syndrome (ARDS), ischemia reperfusion injury, arthritis, & inflammatory bowel disease. ARDS occurs with infections, trauma, & burns, and is 50-70% fatal. For ischemia, NEIs have shown efficacy is animal heart attack models. In 1990 the company's lead bradykinin antagonist, CP-0127, was discovered. CP-0127 has potential in affecting inflammatory conditions such as septic shock (gram positive & negative), traumatic shock, perioperative pain, asthma, burns, & migraines. The third project is an antigen-specific immunomodulation (ASIM) model. ASIM describes the molecular characteristics of an immune response to a specific antigen. ASIM provides a standardized approach to drug design for immune-related illnesses & allergies by suppressing the abnormal immune response to a specific antigen while leaving the rest of the immune system intact. The model is anticipated to receive broad patent protection for ASIM and provides the potential treatment for any disease which the antigen is the causative agent. Under development are compounds for systemic lupus erythematosus and ragweed allergy.

Cortech Headquarter Location

6840 North Broadway Suite A

Denver, Colorado, 80221,

United States

(303)650-1200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.